Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2020-04-22 Share Issue/Capital Cha…
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
NeuroVive makes a MSEK 20 directed share issue to leading Nordic life science investor Hadean Ventures
Share Issue/Capital Change Classification · 1% confidence The document text explicitly announces a 'directed issue of shares totaling around MSEK 20' to an investor, detailing the subscription price, conditions, and the resulting dilution. This action directly relates to fundraising, financing activities, and changes in the capital structure. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it mentions board representation changes as a condition, the primary focus and action described is the share issuance for capital raising. The document is a press release announcing the transaction, not a formal regulatory filing like a 10-K or a general regulatory announcement (RNS), making CAP the most specific fit.
2020-04-22 English
Kallelse till årsstämma i NeuroVive Pharmaceutical AB (publ)
AGM Information Classification · 1% confidence The document is titled "Kallelse till årsstämma i NeuroVive Pharmaceutical AB (publ)" which translates to 'Notice of Annual General Meeting' in Swedish. The text details the date, time, location, COVID-19 precautions, requirements for participation (registration, proxy voting), and the proposed agenda for the meeting. The agenda includes items typical for an AGM, such as electing the chairman, approving the annual report (item 7), deciding on profit distribution (item 8b), amending the articles of association (items 9 & 10), setting director/auditor fees (item 12), electing the board/auditor (item 13), and approving remuneration guidelines (item 14). This content clearly identifies the document as the official notice and materials related to the Annual General Meeting.
2020-04-20 Swedish
Notice of Annual General Meeting of NeuroVive Pharmaceutical AB (publ)
AGM Information Classification · 1% confidence The document is explicitly titled 'Notice of Annual General Meeting of NeuroVive Pharmaceutical AB (publ)' and details the date, time, location, COVID-19 precautions, procedures for participation (registration, proxies), the proposed agenda (including election of chair, approval of accounts, remuneration, and amendments to Articles of Association), and specific resolutions to be voted upon. This content perfectly matches the definition of materials shared during an Annual General Meeting (AGM). It is not a full Annual Report (10-K) or a standalone Audit Report (AR), nor is it just an announcement of a report (RPA/RNS), as it contains the substantive details and proposals for the meeting itself. Therefore, the appropriate classification is AGM-R.
2020-04-20 English
NeuroVive offentliggör prospekt och ny finansiell information som återfinns i prospektet med anledning av förestående företrädesemission
Capital/Financing Update Classification · 1% confidence The document is a press release from NeuroVive Pharmaceutical AB dated April 3, 2020, announcing that a prospectus ('Prospektet') related to a rights issue ('företrädesemission') has been approved and registered by the Swedish Financial Supervisory Authority (Finansinspektionen). The text explicitly states that the prospectus contains new financial information (capital structure and net debt as of Jan 31, 2020) and provides links to where the prospectus can be found. Crucially, the document itself is an announcement about the publication of the prospectus, not the prospectus or the underlying financial report itself. Since the primary purpose is to announce the publication of a document (the prospectus) and provide details about a corporate action (rights issue), it fits best under the category for announcing the release of reports or general regulatory announcements. Given the context of a rights issue and the publication of a prospectus, this is a significant corporate action announcement. While it contains financial data, the core action is the publication announcement. This aligns most closely with 'Report Publication Announcement' (RPA) or potentially 'Capital/Financing Update' (CAP). Since it explicitly announces the approval and availability of the 'Prospektet' (which is a key document in a financing round), CAP is highly relevant, but the structure strongly suggests an announcement of a publication. However, the financing activity (rights issue) is the central theme. A rights issue is a form of capital raising. Therefore, 'Capital/Financing Update' (CAP) is the most specific fit for the underlying event, even though the format is an announcement of the prospectus publication. If the document were the prospectus itself, it would be CAP or potentially a specialized prospectus filing type not listed. Given the options, CAP captures the essence of the rights issue announcement.
2020-04-03 Swedish
NeuroVive publishes prospectus and new financial information included in the prospectus in connection with forthcoming rights issue
Capital/Financing Update Classification · 1% confidence The document is a press release dated April 3, 2020, announcing that NeuroVive has prepared and received approval for a 'Prospectus' in connection with a 'forthcoming rights issue' (a capital raising activity). It explicitly states that the Prospectus contains new financial information (capital structure as of Jan 31, 2020) and details the terms of the Rights Issue. Since the document's primary function is to announce the publication and availability of a formal document (the Prospectus) related to a capital raising event, it fits best under the category describing the announcement of a report or regulatory filing, or a specific financing event. Given the focus on the 'Prospectus' publication and the details of the 'Rights Issue' (a capital/financing activity), the most precise classification is 'Capital/Financing Update' (CAP). While it announces a prospectus, the core subject matter is the financing structure itself. If the document were the full prospectus, it might be CAP or potentially LTR/RPA depending on jurisdiction, but as an announcement detailing the financing terms and attaching the prospectus, CAP is the strongest fit among the provided options, as it directly relates to fundraising and capital structure changes.
2020-04-03 English
NeuroVive Pharmaceutical AB (publ): kommuniké från extra bolagsstämma
Share Issue/Capital Change Classification · 1% confidence The document is titled "NeuroVive Pharmaceutical AB (publ): kommuniké från extra bolagsstämma" (communication from the extraordinary general meeting). It details decisions made at this meeting, specifically focusing on the approval of a rights issue (nyemission av aktier med företrädesrätt) which is a significant capital/financing activity. Although it discusses a shareholder meeting (AGM/EGM context), the core subject is the capital change resulting from the meeting's decision. The filing is a formal announcement summarizing the outcome of a shareholder vote regarding a capital increase. This aligns best with the 'Capital/Financing Update' (CAP) category, as the primary financial action being communicated is the rights issue raising approximately 74 MSEK. While it relates to a general meeting, the substance is the capital structure change, making CAP more specific than AGM-R or DVA (which focuses only on voting results, not the underlying financial action). Given the explicit details of the share issue, subscription dates, and price, CAP is the most appropriate classification.
2020-03-17 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.